Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia.

Xiao YU; Caixia LI; Xiaojin WU; Lu YE; Hong LIU; Chao MA; Jinfeng MA; Caihong GU; Depei WU

Return

Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia.

VernacularTitle:二代酪氨酸激酶抑制剂联合异基因造血干细胞移植治疗Ph染色体阳性白血病
Author: Xiao YU ¹ ; Caixia LI ¹ ; Xiaojin WU ¹ ; Lu YE ¹ ; Hong LIU ¹ ; Chao MA ¹ ; Jinfeng MA ¹ ; Caihong GU ¹ ; Depei WU ¹
Author Information

1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Publication Type:Journal Article
MeSH: Adolescent; Adult; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; therapy; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; therapy; Protein Kinase Inhibitors; therapeutic use; Protein-Tyrosine Kinases; antagonists & inhibitors; Retrospective Studies; Transplantation, Homologous; Young Adult
From: Chinese Journal of Hematology 2014;35(2):129-133
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the efficacy and safety of second-generation tyrosine kinase inhibitors (TK-II) combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of high-risk Philadelphia chromosome positive (Ph⁺) leukemia.
METHODSThe clinical data of 17 cases of high-risk Ph⁺ leukemia patients underwent allo-HSCT were retrospectively analyzed, including 1 case in accelerated phase and 7 cases in blast crises of chronic myeloid leukemia, and 9 cases of Ph⁺ acute lymphoblastic leukemia. Nilotinib or Dasatinib were administered before and (or) after allo-HSCT in all patients.
RESULTSAll patients successfully engrafted. Median times to neutrophil and platelet recovery were 12 days (range 10-14) and 15 days (range 11- 23), respectively. Acute GVHD developed in 7 patients: 6 patients had grade 1 to 2 and 1 patient grade 3. Chronic GVHD developed in 6 patients, all were limited and no lethal GVHD occurred. At a median follow-up of 17(range 3-60) months, 11(64.7%) patients survived disease free, 6 patients relapsed and 5 died.
CONCLUSIONTK-II combined with allo-HSCT effectively improved the remission rate of high-risk Ph⁺ leukemia and reduced recurrence after allo-HSCT, which represented an important improvement in the treatment of patients with high-risk Ph+ leukemia.